Lipitas F 160mg/5mg Tablet is a combination lipid-lowering agent containing Fenofibrate 160mg and Rosuvastatin 5mg. Fenofibrate, a fibric acid derivative, primarily reduces triglyceride levels and increases high-density lipoprotein cholesterol (HDL-C) by activating peroxisome proliferator-activated receptor alpha (PPARα), which enhances lipolysis and elimination of triglyceride-rich particles. Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively lowers low-density lipoprotein cholesterol (LDL-C) and total cholesterol by inhibiting the rate-limiting step in cholesterol biosynthesis in the liver. This combination is indicated for the management of mixed dyslipidemia, including hypertriglyceridemia and elevated LDL cholesterol, particularly in patients who require dual lipid modification. Lipitas F is beneficial in reducing cardiovascular risk associated with atherogenic dyslipidemia. It should be used adjunctively with diet and lifestyle modifications such as exercise, weight control, and smoking cessation. Caution is advised in patients with hepatic or renal impairment, and periodic monitoring of liver function tests and creatine kinase levels is recommended to detect potential adverse effects such as hepatotoxicity or myopathy. Lipitas F should be prescribed under medical supervision with appropriate patient education on adherence and monitoring.